Axcentua files two US provisional patent applications

Nov 12, 2008

Axcentua has today filed two US provisional applications covering the lead clinical candidate AXP107-11.
The compound has been re-engineered by Axcentua from a natural compound that target
multiple signaling pathways implicated in cancer. To submit the patent applications Axcentua has worked together with Jeffrey A. Lindeman (Ph. D.) who is an internationally well renowned specialist in patents on crystalline forms of active pharmaceutical ingredients (APIs) at the "Global 100" law" firm Nixon Peabody LLP.